



## Therapy for retinal degeneration in ciliopathies



Pharmacological therapy to slow significantly retinal degeneration linked to protein trafficking defect inducing a Unfolded Protein Response

## **6** KEYWORDS

Photoreceptor cell,
Retinitis pigmentosa,
Cellular protein overload,
Endoplasmic reticulum
stress,
Apoptosis,
rare diseases

### **O PATENTS**

WO2013124484

## **6 INVENTORS**

H. Dollfus V. Marion

A. Mockel

Laboratory of Medical Genetics


Unistra / INSERM

# 6

## **TECHNOLOGY**

Impaired intraciliary transport observed in Bbs12-/- murine model

- results in protein retention in the endoplasmic reticulum
- this leads to a proapoptotic unfolded protein response (UPR) triggering death of the photoreceptors
- BiP, and PERK-mediated phosphorylation of eIF2a have been identified as 2 key UPR actors (Mockel et al., 2012)
- GV-ReT is a combination of clinically validated molecules (Valproic Acid and Guanabenz) for the treatment of ciliarelated retinal degeneration



## **APPLICATION**

• Pharmacological therapy for ciliopathy related retinal degeneration

## INNOVATION ADVANTAGES

- A combination of two approved drugs, with a well defined MoA
- Effective in protecting retinal cells from dying and significantly increasing light detection capacity
- Aims at preserving the vision loss and slowing the retinal defects to cure secondarily with a more targeted therapy
- Positions on early onset of the retinal degeneration
- Applicable to different paradigms of retinal degeneration: UPR-inducing ciliopathies, retinal degeneration linked to protein trafficking defect inducing a UPR

## **DEVELOPMENT STATUS**

- Compelling ex vivo and in vivo data establishing the efficacy of this drug combination
- Efficacy assessed on different cilia-related retinal degeneration (Bardet Biedl syndrome, Leber Congenital Amaurosis )

Partnership: program available for out-licensing

**O** CONTACT

Parc d'Innovation 650 Bd Gonthier d'Andernach 67400 ILLKIRCH - FRANCE www.satt.conectus.fr